Posts by Sandra Ansanay-Alex
4 new Medtech Start-Ups join the DayOne Tech Accelerator in Canton of Jura
The DayOne Tech accelerator for medtech project is a pillar of the Jura’s medical technology economy. Four new start-ups joined the programme and the six companies already involved in Courroux. They begin a 12-month acceleration programme with expert support. The aim is to propel them into the ranks of successful companies. Xana…
Read MoreInnovations at the CHUV in the treatment of lymphoedema
Swelling of one or more limbs as a result of lymphoedema – a common but little-understood condition – affects one in five women undergoing breast cancer surgery following the operation. The CHUV is offering two promising new methods for treating this condition. The lymphatic network comprises vessels, lymph nodes and organs that circulate…
Read MoreCHF 3 Million for Terapet and two South Korea partners
Terapet SA together with their South Korean partners Yonsei Cancer Center (Heavy Ion Therapy Center) and Oncosoft Inc. are awarded CHF 3 Million in non-dilutive funds through a bilateral innovation project funded by Innosuisse and the Korea Institute for Advancement of Technology (KIAT). Terapet SA, a Geneva-based CERN spin-off developing an innovative platform…
Read MoreA CHF multimillion investment for Mimix Biotherapeutics
Mimix Biotherapeutics in Biel (Bern) secures significant investment to translate and commercialize a new treatment technique for human tissue regeneration. The strategic investors are supporting MimiX’s vision to transform the lives of millions of patients suffering from chronic wounds. The investment will accelerate the development and commercialization of FastSkin®, a revolutionary treatment that…
Read MoreBioArk Monthey: a 3rd building dedicated to life sciences and biotechnologies
BioArk is on a roll! The Monthey-based technology site, which is celebrating its 20th anniversary this year, inaugurated its third building on Friday 13 October 2023. And it is almost already full! This new showcase, which houses companies specialising in life sciences and biotechnology, is already virtually full. It is proof that The…
Read MoreBioAlps Association Privacy Policy
BioAlps Association’s Privacy Statement: The purpose of this Privacy Policy is to inform you of the procedures regarding the collection, use and disclosure of information on the BioAlps website, including any mobile versions or related mobile applications, collectively called BioAlps Association Sites. 1. About BioAlps Association Founded in 2003, BioAlps Association empowers the…
Read MoreGeneral Terms and Conditions
General Terms and Conditions – BioAlps Association Use of material on this website Material and database on this website may be reproduced, made available or revised for derivative works on other websites or databases without express permission which can be obtained from contact@bioalps.org. You may link to the relevant page on this website…
Read MoreLonza further expands in Visps thanks to a new partnership
A new agreement with an undisclosed global biopharmaceutical partner will quadruple current dedicated bioconjugation capacity by adding two new production units for the commercial supply of Antibody-Drug Conjugates (ADC) at Lonza’s Ibex® Dedicate biopark in Visp (CH). 180 jobs will be created. The announcement of Moderna’s departure does not hinder Lonza’s expansion! This…
Read MoreNovostia starts clinical trials of its new heart valve in Lituania
Novostia has received the green light from the Lithuanian State Health Care Accreditation Agency under the Ministry of Health to launch the First-in-Human implantations (FIH) of its aortic heart valve prosthesis: the TRIFLO. These implants are scheduled to begin in December 2023, at Vilnius University Hospital Santaros Klinikos, under the supervision of Professor Kęstutis…
Read MoreMedicrops acquires Swiss Alpinopharma
A strategic move to enhance digital patient care in the booming European cannabis market. MediCrops Holding AG (‘MediCrops’), based in Schwyz and at Biopôle in Lausanne, has acquired Berlin-based company Swiss Alpinopharma GmbH (‘Swiss Alpinopharma’), a disruptive market leader in the field of medical cannabis and owner of telemedicine platform Enmedify. Swiss Alpinopharma…
Read More